|
KMID : 1101420170490020099
|
|
Korean Journal of Clinical Laboratory Science
2017 Volume.49 No. 2 p.99 ~ p.107
|
|
|
The Inhibitory Effects of Cordycepin on Phosphoproteins including PI3K, Akt, and p38
|
|
Kwon Hyuk-Woo
Lee Dong-Ha
|
|
|
Abstract
|
|
|
|
A species of Cordyceps, an ingredient in Chinese traditional medicine well-known for its major component, cordycepin (3'-deoxyadenosine), has been known to have antiplatelet effects; however, its effects on regulation of phosphoprotein have not been fully elucidated. In this study, we investigated how cordycepin regulates the phosphoprotein, including phosphatidylinositol 3-kinase (PI3K)/Akt and p38, to inhibit platelet aggregation, which are concerned with fibrinogen binding to glycoprotein IIb/IIIa (αIIb/Β3) and granule secretion in platelets. Our finding suggests that cordycepin inhibits collagen-induced platelet aggregation with 261.1 μM of IC50 and also inhibits fibrinogen binding to αIIb/Β3 by a suppression of PI3K/Akt phosphorylation in a dose dependent manner. In addition, cordycepin further showed to inhibit collagen-induced p38 phosphorylation, reducing granule secretion (i.e. ATP- and serotonin-release) and thromboxane A2 (TXA2) production without regulating cyclooxygenase-1 (COX-1) and thromboxane A synthase (TXAS) activities, as well as phospholipase C-γ2 (PLC-γ2) phosphorylation. In conclusion, these results demonstrate that cordycepin-mediated antiplatelet effects were due to the inhibition of fibrinogen binding to αIIb/Β3 via the suppression of PI3K/Akt phosphorylation and inhibition of granule secretion & TXA2 production by suppressing p38 phosphorylation. These results strongly indicate that cordycepin might have therapeutic or preventive potential for platelet aggregation-mediated disorders, regulating the phosphoprotein, including PI3K/Akt and p38.
|
|
|
KEYWORD
|
|
|
Cordycepin, Platelets, PI3K, Akt, p38
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|